SCHEMBL7126568

SCHEMBL7126568

O=C(O)c1cccc(-c2ccsc2)c1F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 2/20 0.51
ACMSD Q8TDX5 2/20 0.46
GPR35 Q9HC97 1/20 0.41
HNF4A P41235 1/20 0.41
TMIGD3 P0DMS9 2/20 0.40
ADORA2A P29274 2/20 0.40
ADORA1 P30542 1/20 0.40
CYP2E1 P05181 1/20 0.40
CYP2A6 P11509 1/20 0.40
CYP2B6 P20813 1/20 0.40
HSD17B10 Q99714 1/20 0.40
ALB P02768 1/20 0.40
LCK P06239 1/20 0.39
FYN P06241 1/20 0.39
DAO P14920 1/20 0.39
KAT6A Q92794 1/20 0.39
KDM4E B2RXH2 1/20 0.38
ASPH Q12797 1/20 0.38
KDM8 Q8N371 1/20 0.38
EIF4E P06730 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1526618 0.83 ACMSD (0.51) DHODHACMSDGPR35HNF4ACYP2E1
SCHEMBL7130701 0.82 SLC6A3 (0.49) DHODHTMIGD3ADORA2AHSD17B10KDM4E
SCHEMBL7119865 0.81 G6PD (0.47) DHODHACMSDGPR35HNF4ACYP2E1
SCHEMBL121804 0.79 HNF4A (0.63) DHODHACMSDHNF4AHSD17B10ALB
SCHEMBL19923221 0.78 HSD17B10 (0.59) DHODHACMSDHNF4AHSD17B10ALB
SCHEMBL16875857 0.77 GPR35 (0.41) DHODHACMSDGPR35TMIGD3ADORA2A
SCHEMBL9358502 0.76 SLC6A4 (0.51) DHODHACMSDGPR35HNF4AHSD17B10
SCHEMBL21944859 0.76 TMIGD3 (0.48) ACMSDTMIGD3ADORA2AADORA1CYP2E1
SCHEMBL15025193 0.75 ACMSD (0.59) ACMSDGPR35TMIGD3ADORA2AADORA1
SCHEMBL6438260 0.75 PDGFRB (0.45) TMIGD3ADORA2AADORA1CYP2E1CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176454-A1 N-coating heterocyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-09-18 US disclosed
WO-2001087845-A2 N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176454-A1 N-coating heterocyclic compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 DHODH 2195/4885ACMSD 87/4885GPR35 633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.